Semaglutide in Nonalcoholic Fatty Liver Disease
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: liver, addiction
- Who it enrolls
- age 18 Years to 75 Years; BMI ≥30 required; conditions: Non-alcoholic Fatty Liver Disease
- Interventions
- Rybelsus Oral Product; Ozempic Injectable Product; Tocopherol and/or Actos
- Conditions
- Non-alcoholic Fatty Liver Disease
- Phase and size
- Phase 4 · 180 participants
- Dates
- Start 2023-02-15
Primary completion 2024-02-15 - Sponsor
- Zagazig University (Other gov)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- NAFLD regression48 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Patients diagnosed with NAFLD by non-invasive methods in the form of abdominal US or MRI, confirmed by a Fibroscan scan with CAP to assess the quantity of hepatic steatosis and severity of fibrosis up to 21 weeks before the start of the study and after treatment. * Primary obesity with body mass index (BMI) \> 30. * Type 2 diabetes mellitus. Exclusion Criteria: * Type 1 diabetes mellitus. * DM, which is treated with insulin glargine. * Alcohol consumption. * Patients had bariatric surgery. * Hepatitis C virus, hepatitis B virus, HIV. * Patients with peptic ulcer disease. * Secondary obesity originated from hypothalamic or endocrinal disorders. * Other causes of CLD. * Decompensated liver disease. * History of pancreatitis (acute or chronic). * Hepato-biliary disorders. * ALT and AST values \> 5 times of upper normal limits. * Severe cardiac disease. * Patients treated with GLP-1 agonist within 90 days before screening. * Patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
03Change log
Registry changes
No changes recorded since the trial was added.